First Patient Dosed in ProstACT Program for Prostate Cancer Therapy

Telix Pharmaceuticals Limited is pleased to announce that the first patient has been dosed in the company’s prostate-specific membrane antigen targeting ‘ProstACT’ therapeutic program, which is exploring TLX591 in areas of unmet medical need across the full prostate cancer treatment journey.
[Telix Pharmaceuticals Limited]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

E2F Transcription Factor 2-Activated DLEU2 Contributes to Prostate Tumorigenesis by Upregulating Serum and Glucocorticoid-Induced Protein Kinase 1

Researchers suggested that E2F transcription factor 2-activated DLEU2 may function as a competing endogenous RNA to facilitate prostate cancer progression by targeting the miR-582-5p/SGK1 axis.
[Cell Death & Disease]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration Resistant Prostate Cancer

DNA-dependent kinase catalytic subunit (DNA-PK) regulation of metabolism was interrogated using pharmacological and genetic perturbation using in vitro cell models, in vivo xenografts, and ex vivo in patient-derived explants
[Clinical Cancer Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull Article
Bookmark

No account yet? Register

Share

THEM6-Mediated Reprogramming of Lipid Metabolism Supports Treatment Resistance in Prostate Cancer

Scientists identified thioesterase superfamily member 6 (THEM6) as a marker of androgen-deprivation therapy resistance in prostate cancer. THEM6 deletion reduced in vivo tumor growth and restored castration sensitivity in orthograft models of CRPC.
[EMBO Molecular Medicine]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

ATF6α Promotes Prostate Cancer Progression by Enhancing PLA2G4A-Mediated Arachidonic Acid Metabolism and Protecting Tumor Cells against Ferroptosis

Researchers found that the increase of transcription factor 6 α (ATF6α) expression in response to androgen deprivation generated prostate cancer cells with a CRPC-like phenotype.
[Prostate]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Targeting a Splicing-Mediated Drug Resistance Mechanism in Prostate Cancer by Inhibiting Transcriptional Regulation by PKCβ1

PKCβ inhibition reduced total androgen receptor (AR) gene expression, thus reducing AR-V7 protein levels and sensitizing prostate cancer cells to current anti-androgen therapies.
[Oncogene]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Gene Therapy of Prostate Cancer Using Liposomes Containing Perforin Expression Vector Driven by the Promoter of Prostate-Specific Antigen Gene

The authors investigated the therapeutic potential of liposomes containing perforin expression vector driven by the promotor of prostate-specific antigen.
[Scientific Reports]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Olaparib Induced Senescence is Bypassed through G2/M Checkpoint Override in Olaparib Resistant Prostate Cancer

Investigators characterized responses to olaparib in sensitive LNCaP and C4-2B cells and developed two olaparib resistant derivative cell line models from each. In LNCaP and C4-2B cells, they found that olaparib induced massive DNA damage, leading to activation of the G2/M checkpoint, activation of p53, and cell cycle arrest.
[Molecular Cancer therapeutics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-Type Prostate Cancer Models

Scientists investigated the response of PTEN wild-type prostate cancer cell lines to the dual PI3K/mTOR inhibitor DS-7423 alone or in combination with HER2 inhibitors or mGluR1 inhibitors.
[Molecular Cancer therapeutics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull Article
Bookmark

No account yet? Register

Share

NCAPD3 Promotes Prostate Cancer Progression by Up-Regulating EZH2 and MALAT1 through STAT3 and E2F1

In vitro and in vivo functional characterization revealed that overexpression of NCAPD3 enhanced the growth of prostate cancer (PCa) cells, while knockdown of NCAPD3 impaired the growth of PCa cells.
[Cellular Signalling]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer

Integrated copy number aberration and gene expression analysis of primary high-risk prostate cancer identified the AZIN1 gene as a novel driver of metastatic progression, by altering collagen subunit expression.
[Molecular Cancer Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share